Bevacizumab在眼表疾病中的应用  

Application of Bevacizumab in ocular surface diseases

作　　者：宋莉[1] 沙翔垠[1] 

机构地区：[1]广州医学院第二附属医院眼科,广东省广州市510260

出　　处：《眼科新进展》2010年第5期497-500,共4页Recent Advances in Ophthalmology

摘　　要：眼表疾病是临床常见的致盲眼病,特别是角膜新生血管性眼病因其发病机制非常复杂,治疗棘手而成为眼科新研究领域一大难点和热点。Bevacizumab给药靶向阻断血管内皮生长因子及其受体,有效抑制新生血管生长,其抗淋巴血管性、抗纤维性有望成为角膜移植术后免疫排斥反应、LASIK术前常规及预防用药,现综述如下。Ocular surface disease is a common eye disease to cause blindness,in particular,corneal neovascularization is a hot spot of ophthalmic research for its complicated pathogenesis and difficult treatment.Bevacizumab administration can target blocking vascular endothelial growth factor and its receptors,effectively inhibit the growth of new blood vessels.Its lymphatic vascular resistance and anti-fibrosis are expected to become conventional and prophylactic agents for immunologic rejection after keratoplasty or before LASIK.All above are reviewed.

关 键 词：BEVACIZUMAB 眼表疾病 血管内皮生长因子 

分 类 号：R772.2[医药卫生—眼科] R777.3[医药卫生—临床医学]